

AN EVENING WITH THE INVESTIGATORS

Perspectives on Key Questions and Emerging Research in the Management of Lymphoma and Multiple Myeloma

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

Hematologic cancers include the lymphomas, the leukemias, multiple myeloma (MM) and other related disorders (eg, myelodysplastic syndrome, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that 172,910 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2017 and 58,300 individuals will die from these diseases. Importantly, nearly 70 drug products with more than 120 distinct FDA-approved indications are currently labeled for use in the management of hematologic cancers. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true, however, within the realm of Hodgkin and non-Hodgkin lymphoma (including chronic lymphocytic leukemia [CLL]) and MM, where the past several years have seen a staggering number of important clinical and research advances.

These video proceedings from a CME symposium held during the 2017 ASCO Annual Meeting feature discussions with leading researchers with expertise in hematologic cancers regarding the latest clinical research findings and actual patient cases from their practices for whom these data sets had the potential to have an impact on care. By providing information on the latest research developments and their potential application to routine practice, this activity is designed not only to improve clinicians' knowledge of recent data related to the rapidly evolving hematologic oncology treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.

LEARNING OBJECTIVES

- Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
- Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with relapsed/refractory MM.
- Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory CLL, considering clinical presentation, biomarker profile and psychosocial status.
- Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
- Assess the benefits and risks of evidence-based systemic treatment options to individualize and optimize the care of patients with T-cell lymphoma.
- Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with Hodgkin lymphoma (HL) and other CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
- Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of HL, non-Hodgkin lymphoma (NHL), CLL and MM to determine the current and/or potential utility of each in clinical practice.
- Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL, CLL and MM, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOHem17/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Stephen M Ansell, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Contracted Research: Affimed, Bristol-Myers Squibb Company, Celldex Therapeutics, Merck, Pfizer Inc, Seattle Genetics.

Michelle A Fanale, MD

Associate Professor
Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Merck, Spectrum Pharmaceuticals Inc; **Honoraria:** Plexus, Seattle Genetics, Takeda Oncology; **Travel:** Bristol-Myers Squibb Company, Merck, Plexus, Spectrum Pharmaceuticals Inc, Takeda Oncology.

Christopher Flowers, MD, MS

Associate Professor of Hematology and Medical Oncology
Emory School of Medicine Winship Cancer Institute
Atlanta, Georgia

Consulting Agreements: AbbVie Inc, Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc; **Contracted Research:** AbbVie Inc, Acerta Pharma, Eastern Cooperative Oncology Group, Genentech BioOncology, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc.

Jonathan W Friedberg, MD, MMSc

Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Data and Safety Monitoring Board: Bayer HealthCare Pharmaceuticals.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Celgene Corporation, Novartis; **Contracted Research:** AstraZeneca Pharmaceuticals LP, Lilly.

S Vincent Rajkumar, MD

Edward W and Betty Knight Scripps Professor of Medicine
Division of Hematology
Chair, Myeloma Amyloidosis Dysproteinemia Group
Mayo Clinic
Rochester, Minnesota

No relevant conflicts of interest to disclose.

MODERATOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educa-

tional grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Kite Pharma Inc and Seattle Genetics.

Hardware/Software Requirements:

A high-speed Internet connection

A monitor set to 1280 x 1024 pixels or more

Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

Adobe Flash Player 10.2 plug-in or later

Adobe Acrobat Reader

(Optional) Sound card and speakers for audio

Last review date: August 2017

Expiration date: August 2018

Select Publications

A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL). NCT02048813

Andorsky DJ et al. **Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).** *Proc ASCO* 2017;Abstract 7502.

Armand P et al. **Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.** *J Clin Oncol* 2016;[Epub ahead of print].

Badros A et al. **Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma.** *Blood* 2017;[Epub ahead of print].

Barr P et al. **Updated efficacy and safety from the phase 3 Resonate-2 study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia.** *Proc ASH* 2016;Abstract 234.

Byrd JC et al. **Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia.** *N Engl J Med* 2016;374(4):323-32.

Chen R et al. **Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma.** *J Clin Oncol* 2017;35(19):2125-32.

Cohen A et al. **B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): Initial safety and efficacy from a phase I study.** *Proc ASH* 2016;Abstract 1147.

Davies A et al. **Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): A randomised, open-label, phase 3 trial.** *Lancet Haematol* 2017;4(6):e272-82.

Fink AM et al. **Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: Interim results of a phase 3 Study (CLL M1 study of the German CLL Study Group).** *Proc ASH* 2016;Abstract 229.

Foa R et al. **Results of the phase 3 study of lenalidomide versus placebo as maintenance therapy following second-line treatment for patients with chronic lymphocytic leukemia (the CONTINUUM trial).** *Proc ASH* 2016;Abstract 230.

Gallamini A et al. **A phase 1/2 clinical trial of brentuximab-vedotin and bendamustine in elderly patients with previously untreated advanced Hodgkin lymphoma (HALO STUDY. NCT identifier: 02467946): Preliminary report.** *Proc ASH* 2017;Abstract 4154.

Jakubowiak AJ et al. **Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.** *Proc ASCO* 2017;Abstract 8000.

Laubach J et al. **An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.** *Proc ASCO* 2017;Abstract 8002.

Lonial S et al. **Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).** *Proc ASCO* 2017;Abstract 8028.

Marcus RE et al. **Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: Primary results of the randomized phase 3 GALLIUM study.** *Proc ASH* 2016; Abstract 6.

Munshi N et al. **Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis.** *JAMA Oncol* 2017;3(1):28-35.

Roemer MG et al. **PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome.** *J Clin Oncol* 2016;34(23):2690-7.

Roussel M et al. **Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: Primary results of the Intergroupe Francophone Du MyéLome (IFM) Krd phase II study.** *Proc ASH* 2016;Abstract 1142.

Siegel DS et al. **Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: A pooled analysis of three clinical trials.** *Leuk Lymphoma* 2016;57(12):2833-8.

Sweetenham JW et al. **Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse.** *Biol Blood Marrow Transplant* 2016;22(3):S36-7.

Select Publications

Usmani SZ et al. **Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO).** *Proc ASH 2016*;Abstract 1149.

Younes A et al. **Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial.** *Lancet Oncol 2016*;17(9):1283-94.

Zelenetz AD et al. **Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL.** *Proc ASH 2016*;Abstract 231.